Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: New therapeutic approaches

Rheumatology (United Kingdom)

Volumn 55, Issue 12, 2016, Pages 2096-2108

  López Pedrera, Chary ^a   Barbarroja, Nuria ^a   Jimenez Gomez, Yolanda ^a   Collantes Estevez, Eduardo ^a   Aguirre, Ma Angeles ^a   Cuadrado, Ma Jose ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti phospholipid syndrome; Atherothrombosis; Oxidative stress; Systemic lupus erythematosus; Therapeutic approaches

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UBIDECARENONE; ANTIOXIDANT; AUTOANTIBODY; COAGULATING AGENT; REACTIVE OXYGEN METABOLITE; UBIQUINONE;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; COMPLICATION; INFLAMMATION; METABOLISM; MITOCHONDRIAL DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE;

ACETYLCYSTEINE; ANTICOAGULANTS; ANTIOXIDANTS; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; COAGULANTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECURRENCE; THROMBOSIS; UBIQUINONE;

EID: 85013998847     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew054     Document Type: Review

References (99)

1. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47.
2. Solté sz P, Kerekes G, Dér H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011;10:416-25.
3. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-41.
4. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogenactivated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-b2Glycoprotein I antibodies. Int Immunol 2004;16:1633-41.
5. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006;4:2461-9.
6. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum 2010;62:869-77.
7. López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kB/ Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-11.
8. López-Pedrera C, Cuadrado MJ, Herández V, et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008;58:2835-44.
9. Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009;302:1210-7.
10. Ames PR, Matsuura E, Batuca JR, et al. High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 2010;19:711-6.
11. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 2012;119:5859-70.
12. Jiménez S, García-Criado MA, Ta`ssies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005;44:756-61.
13. Cugno M, Borghi MO, Lonati LM, et al. Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 2010;34:105-10.
14. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of b2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73.
15. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012;8:214-23.
16. Pengo V, Bison E, Ruffatti A, et al. Autoantibodies to oxidized LDL/b2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res 2008;122:556-9.
17. Firuzi O, Fuksa L, Spadaro C, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006;58:951.
18. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009;73:977-85.
19. Rho YH, Chung CP, Oeser A, et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res 2010;62:1473-80.
20. Khan F, Siddiqui AA. Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus. Clin Chim Acta 2006;370:100-7.
21. Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell Biochem 2008;49:325-50.
22. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 2003;5:383-90.
23. Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996;51:1-9.
24. Iuliano L, Practico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931-5.
25. Matsuura E, Kobayashi K, Lopez LR. Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep 2009;11:61-9.
26. Sciascia S, Roccatello D, Bertero MT, et al. 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflamm Res 2012;61:809-16.
27. Delgado AJ, Mason LJ, Ames PR, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology 2005;44:1238-44.
28. Prinz N, Clemens N, Strand D, et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011;118:2322-32.
29. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
30. Matsuura E, Lopez LR. Autoimmune-mediated atherothrombosis. Lupus 2008;17:878-87.
31. Giannakopoulos B, Krilis A. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033-44.
32. Passam FH, Rahgozar S, Qi M, et al. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 2010;116:1995-7.
33. Passam FH, Rahgozar S, Qi M, et al. Redox control of b2-glycoprotein I-von Willebrand factor interaction by thioredoxin-J Thromb Haemost 2010;8:1754-62.
34. Ioannou Y, Zhang JY, Qi M, et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen b2-glycoprotein I. Arthritis Rheum 2011;63:2774-82.
35. Ioannou Y, Zhang JY, Passam FH, et al. Naturally occurring free thiols within b2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 2010;116:1961.
36. Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010;116:1336-43.
37. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008;7:567-73.
38. Kumagai S, Jikimoto T, Saegusa J. Pathological roles of oxidative stress in autoimmune diseases. Rinsho Byori 2003;51:126-32.
39. Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun Rev 2008;7:544-9.
40. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 2003;131:398-404.
41. Perl A, Hanczko R, Doherty E. Assessment of mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol Biol 2012;900:61-89.
42. Shah D, Sah S, Nath SK. Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmun Rev 2013;12:741-51.
43. Shah D, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 2014;21:23.
44. Lopez LR, Simpson DF, Hurley BL, Matsuura E. OxLDL/ b2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 2005;1051:313-22.
45. Yălmaz S, Caliskan M, Kulaksăzoglu S, et al. Association between serum total antioxidant status and coronary microvascular functions in patients with SLE. Echocardiography 2012;29:1218-23.
46. Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis 2015;74:1450-8.
47. Oka T, Hikoso S, Yamaguchi O, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012;485:251-5.
48. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007;176:231-41.
49. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
50. Brinkmann V, Laube B, Abu Abed U, Goosmann C, Zychlinsky A. Neutrophil extracellular traps: how to generate and visualize them. J Vis Exp 2010;36:1724.
51. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1777-83.
52. Kambas K, Chrysanthopoulou A, Vassilopoulos D, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2014;73:1854-63.
53. Grässle S, Huck V, Pappelbaum KI, Gorzelanny C, et al. von Willebrand factor directly interacts with DNA from neutrophil extracellular traps. Arterioscler Thromb Vasc Biol 2014;34:1382-9.
54. Brill A, Fuchs TA, Savchenko A, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2011;10:136-44.
55. von Brühl ML, Stark K, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819-35.
56. Gupta AK, Joshi MB, Philippova M, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett 2010;584:3193-7.
57. Villanueva E, Yalavarthi S, Berthier CC. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol 2010;187:538-52.
58. Megens RT, Vijayan S, Lievens D, et al. Presence of luminal neutrophils extracellular traps in atherosclerosis. Thromb Haemost 2012;107:597-8.
59. Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012;287:6375-86.
60. Griendling KK. Novel NADPH oxidases in the cardiovascular system. Heart 2004;90:491-3.
61. Tsutsui M, Shimokawa H, Otsuji Y, Yanagihara N. Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacol Ther 2010;128:499-508.
62. Döring Y, Drechsler M, Wantha S, et al. Lack of neutrophilderived CRAMP reduces atherosclerosis in mice. Circ Res 2012;110:1052-6.
63. Liu ML, Bashir M, Williams K, Werth V. Cholesterol loading induces neutrophil extracellular traps, and atorvastatin attenuates this effect. Abstract 1208. Presented at the 2014 ACR/ARHP Annual Meeting, Boston, MA, USA.
64. Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived form neutrophils extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Frontiers Immunol 2012;3:380.
65. Darrah E, Andrade F. NETs: the missing link between cell death and systemic autoimmune diseases? Front Immunol 2013;3:428.
66. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21.
67. Perazzio SF, Salomão R, Silva NP, Andrade LE. Increased neutrophil oxidative burst metabolism in systemic lupus erythematosus. Lupus 2012;21:1543-51.
68. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009;114:2619-22.
69. Lim MB, Kuiper JW, Katchky A, Goldberg H, Glogauer M. Rac2 is required for the formation of neutrophil extracellular traps. J Leukoc Biol 2011;90:771-6.
70. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010;191:677-91.
71. Remijsen Q, Vanden Berghe T, Wirawan E, et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res 2011;21:290-304.
72. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol 2012;198:773-83.
73. Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophils extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010;107:9813-8.
74. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
75. Hacbarth E, Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum 1986;29:1334-42.
76. Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010;184:3284-97.
77. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol 2013;35:455-63.
78. Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis 2014;74:1417-24.
79. Smith CK, Vivekanandan-Giri A, Tang C, et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol 2014;66:2532-44.
80. Yalavarthi S, Mazza LF, Morris AE, et al. Antiphospholipid antibodies promote the release of neutrophil extracellular traps: a new mechanism of thrombosis in the antiphospholipid syndrome. Abstract 2867 Presented at the 2014 ACR/ARHP Annual Meeting, Boston, MA, USA.
81. Md Yusof MY, Vital EM, Emery P. Biologics in systemic lupus erythematosus (SLE): current options and future perspectives. Br J Hosp Med 2014;75:440, 442-7.
82. Bruce IN. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:273-7.
83. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-totarget in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
84. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
85. Pingel S, Tiyerili V, Mueller J, et al. Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch Med Sci 2014;10:154-60.
86. Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012;108:840-8.
87. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
88. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.
89. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-71.
90. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
91. Mensink M, Hesselink MK, Russell AP, et al. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1a and PPARb/d gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes 2007;31:1302-10.
92. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell 2006;127:1109-22.
93. Garcia RJ, Francis L, Dawood M, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:1313-8.
94. Attia FM, Maaty A, Kalil FA. Circulating endothelial cells as a marker of vascular dysfunction in patients with systemic lupus erythematosus by real-time polymerase chain reaction. Arch Pathol Lab Med 2011;135:1482-5.
95. Kudaravalli J. Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Indian J Pharmacol 2011;43:311-5.
96. Lai ZW, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012;64:2937-46.
97. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99.
98. Ames PR, Margarita A, Delgado Alves J, et al. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002;11:208-14.
99. Ong SB, Subrayan S, Lim SY, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 2010;121:2012-22.